Pharmaceutical

BioVaxys and Sona partner to develop cancer therapeutics

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform (DPX) with THT.

May 10, 2025 - 06:00
BioVaxys and Sona partner to develop cancer therapeutics
BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform (DPX) with THT.
Read the original article

Tags:

Previous Article

VC firm Vivo Capital outlays $740m for biotech investment

Next Article

Bisphosphonate Timing Influences Jaw Osteonecrosis Risk

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab

Signal: AbbVie ends multi-million dollar cancer drug de...

Sep 25, 2023

Biotech’s road to recovery with 46% increase in Q1 venture funding

Biotech’s road to recovery with 46% increase in Q1 vent...

May 29, 2024

Opinion: People with food insecurity deserve better nutrition education

Opinion: People with food insecurity deserve better nut...

Dec 27, 2023